banner

News Releases

None | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
Date Title
07/21/21
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
07/21/21
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
07/14/21
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
06/03/21
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
05/26/21
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
05/05/21
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
05/04/21
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
04/21/21
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
04/05/21
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
03/08/21
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
02/24/21
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
02/19/21
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
02/18/21
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
02/10/21
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
01/27/21
Acadia Pharmaceuticals Announces Commercial Leadership Change
12/22/20
Acadia Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021
11/10/20
Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020
11/04/20
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results
10/26/20
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
10/21/20
Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020
10/14/20
The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, “Robin’s Wish”
10/06/20
Michael J. Fox Foundation and Acadia Pharmaceuticals Partner to Share Resources and Foster Dialogue on Cognitive Changes and Other Non-Motor Symptoms in Parkinson’s Disease
10/01/20
Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors
09/02/20
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
08/31/20
ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development
08/25/20
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio
08/12/20
ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020
08/05/20
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results
07/29/20
People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights
07/22/20
ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
07/20/20
ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
07/20/20
ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
06/15/20
ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
06/02/20
ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
05/28/20
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
05/26/20
ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
05/21/20
ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
05/07/20
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results
05/07/20
ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration
05/05/20
ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences
04/15/20
ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020
03/03/20
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome
02/26/20
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
02/24/20
ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020
02/12/20
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020
01/07/20
ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
12/18/19
ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer
12/04/19
ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
11/25/19
ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia
11/11/19
ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
11/04/19
ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
10/30/19
ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
10/30/19
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
10/16/19
ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
10/07/19
ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
10/03/19
ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
09/25/19
ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
09/24/19
ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
09/23/19
ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
09/20/19
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
09/19/19
ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
09/17/19
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
09/17/19
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
09/09/19
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
09/04/19
ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
07/31/19
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
07/22/19
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
07/17/19
ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
06/25/19
New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
06/04/19
ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
05/18/19
ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
05/07/19
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
05/01/19
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
04/25/19
ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
04/17/19
ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
04/11/19
ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
04/02/19
ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
04/01/19
ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
03/27/19
Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
03/04/19
ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
02/26/19
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
02/21/19
ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
02/12/19
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
12/20/18
ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
11/30/18
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/27/18
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
11/26/18
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
11/06/18
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
10/31/18
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
10/29/18
ACADIA Pharmaceuticals Announces Executive Leadership Change
10/23/18
ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
09/26/18
ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
09/25/18
ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
09/20/18
FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
09/10/18
Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
09/04/18
ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
08/08/18
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
08/06/18
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
07/30/18
ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
07/19/18
ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
06/29/18
ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
06/13/18
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
06/06/18
ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
05/08/18
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
05/04/18
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
05/02/18
ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
05/01/18
ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
04/27/18
ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
04/27/18
ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
04/23/18
PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
03/20/18
ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
03/06/18
ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
02/27/18
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
02/20/18
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
01/02/18
ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
12/13/17
ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
11/21/17
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
11/07/17
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
11/03/17
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
10/31/17
ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
10/04/17
ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
09/19/17
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
08/08/17
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
08/01/17
ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
07/25/17
ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
05/09/17
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
05/08/17
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
05/02/17
ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
03/30/17
ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
03/29/17
ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
02/28/17
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
02/27/17
ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
02/21/17
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
01/03/17
ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
12/20/16
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
12/01/16
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder
11/15/16
ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
11/07/16
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
11/03/16
ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
11/01/16
ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
10/31/16
ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation
10/11/16
ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
09/20/16
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
09/19/16
ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
09/06/16
ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016
08/24/16
ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
08/23/16
ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
08/09/16
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
08/08/16
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
08/04/16
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
07/29/16
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
06/27/16
ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index
06/16/16
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
06/01/16
ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
05/31/16
ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
05/05/16
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
05/04/16
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
05/02/16
ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
04/29/16
FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
04/06/16
ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
03/29/16
FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
03/29/16
ACADIA Pharmaceuticals Stock Trading Halted Today
03/01/16
ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
02/29/16
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
02/23/16
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
02/03/16
ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
01/29/16
ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
01/25/16
ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
01/11/16
ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
01/07/16
ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
01/06/16
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
01/05/16
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
12/15/15
ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
11/30/15
ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
11/30/15
ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
11/05/15
ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
11/04/15
ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
11/02/15
ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
10/29/15
ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
09/22/15
ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
09/03/15
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
09/03/15
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
08/06/15
ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
08/06/15
ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
08/05/15
ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
07/30/15
ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
06/17/15
ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
06/16/15
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
05/26/15
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
05/07/15
ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
05/06/15
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
04/30/15
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
04/07/15
ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
03/26/15
ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
03/11/15
ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
03/11/15
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
02/26/15
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
02/24/15
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
02/19/15
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
01/06/15
ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
12/08/14
ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
11/25/14
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
11/13/14
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
11/10/14
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
11/03/14
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
09/02/14
ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
08/28/14
ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
08/05/14
ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
07/29/14
ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
07/15/14
ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
06/17/14
ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
05/27/14
ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
05/06/14
ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
05/01/14
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
04/29/14
ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
04/01/14
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
03/05/14
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
03/04/14
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
03/03/14
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
02/27/14
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
02/20/14
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
11/26/13
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
11/14/13
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
11/06/13
ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
10/31/13
ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
10/30/13
ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
09/03/13
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
08/19/13
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
08/06/13
ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
07/30/13
ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
07/02/13
ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
07/01/13
ACADIA Pharmaceuticals Added to Russell 2000 Index
06/18/13
ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
06/03/13
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
05/29/13
ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
05/20/13
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
05/20/13
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
05/15/13
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
05/14/13
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
05/07/13
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
04/30/13
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
04/25/13
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
04/11/13
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
03/20/13
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
03/13/13
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
03/12/13
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
03/05/13
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
02/25/13
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
02/05/13
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
01/22/13
ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors